Clinical Trial Update: Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports on the safety and preliminary efficacy of Bexxar (tositumomab) in patients with relapsed or residual B-cell non-Hodgkin lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bexxar (tositumomab)

Snippet

Sponsor: University of Pennsylvania | Conditions: B-cell Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED